Ignite Creation Date:
2025-12-24 @ 3:29 PM
Ignite Modification Date:
2026-02-02 @ 8:27 PM
Study NCT ID:
NCT01710592
Status:
COMPLETED
Last Update Posted:
2013-01-10
First Post:
2012-10-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
Sponsor:
Cancer Trials Ireland
Organization:
Organization Data
Organization:
Class:
NETWORK
Study ID:
ICORG 06-05
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NETWORK
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None